Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jane E. Willoughby"'
Autor:
Junping Jing, Laura Bover, C Ian Mockridge, Kerry L Cox, Mark S Cragg, Tatyana Inzhelevskaya, Chris A Penfold, Vikki English, Jane E Willoughby, Hong Shi, Peter J Morley, Heather Jackson, Roopa Srinivasan, Tom Murray, Axel Hoos, Paul Bojczuk, James Smothers, Niranjan Yanamandra, Lang Dou, Sabyasachi Bhattacharya, Laura Seestaller-Wehr, David Kilian, Kui S Voo, Mel John, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Sara J Brett, Christopher Hopson, Elaine Paul, Stephen L Martin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background OX40 has been widely studied as a target for immunotherapy with agonist antibodies taken forward into clinical trials for cancer where they are yet to show substantial efficacy. Here, we investigated potential mechanisms of action of anti-
Externí odkaz:
https://doaj.org/article/1d4a1e220c0f453894379600a08cb4a4
Autor:
C Ian Mockridge, H T Claude Chan, Mark S Cragg, Jinny Kim, Tatyana Inzhelevskaya, Jane E Willoughby, Julia Moreno-Vicente, Martin C Taylor, Steven G Booth, Vikki L English, Emily L Williams, Christine A Penfold, Juliet C Gray, Stephen A Beers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/0d95105e612946869ce83db4c68db191
Autor:
C Ian Mockridge, Kerry L Cox, Martin J Glennie, Mark S Cragg, Monika Semmrich, Linda Mårtensson, Ingrid Teige, Jordana Griffiths, Khiyam Hussain, Hannah L Smith, Theodore Sanders, Jinny Kim, Tatyana Inzhelevskaya, Chris A Penfold, Alison L Tutt, HT Claude Chan, Vikki English, Ruth F French, Aymen Al-Shamkhani, Bjorn L Frendeus, Jane E Willoughby
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Previous data suggests that anti-OX40 mAb can elicit anti-tumor effects in mice through deletion of Tregs. However, OX40 also has powerful costimulatory effects on T cells which could evoke therapeutic responses. Human trials with anti-OX4
Externí odkaz:
https://doaj.org/article/86d9cb4f413b4935a92592aca78649b9
Autor:
Julia Moreno-Vicente, Jane E Willoughby, Martin C Taylor, Steven G Booth, Vikki L English, Emily L Williams, Christine A Penfold, C Ian Mockridge, Tatyana Inzhelevskaya, Jinny Kim, H T Claude Chan, Mark S Cragg, Juliet C Gray, Stephen A Beers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDespite extensive clinical use, the mechanisms that lead to therapeutic resistance to anti-programmed cell-death (PD)-1 monoclonal antibodies (mAbs) remain elusive. Here, we sought to determine how interactions between the Fc region of anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfc1d40f038ae30462935179ccdb7a35
https://jitc.bmj.com/content/10/1/e003735.full
https://jitc.bmj.com/content/10/1/e003735.full
Autor:
Claude H.T. Chan, Hannah L Smith, Theodore Sanders, Mark S. Cragg, Vikki English, Björn Frendéus, Martin J. Glennie, Ingrid Teige, Jordana Griffiths, Ruth R. French, Khiyam Hussain, Chris Penfold, Kerry L. Cox, Jane E. Willoughby, Tatyana Inzhelevskaya, Alison L. Tutt, Ian M Mockridge, Monika Semmrich, Jinny Kim, Aymen Al-Shamkhani, Linda Mårtensson
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundPrevious data suggests that anti-OX40 mAb can elicit anti-tumor effects in mice through deletion of Tregs. However, OX40 also has powerful costimulatory effects on T cells which could evoke therapeutic responses. Human trials with anti-OX40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5298aead16bc1b468e07964d3f14d5f
https://pubmed.ncbi.nlm.nih.gov/33428585
https://pubmed.ncbi.nlm.nih.gov/33428585
Autor:
Jane E. Willoughby, Ivo Tews, Ruth R. French, Chris Orr, Ali Roghanian, Anne White, Stephen A. Beers, Martin J. Glennie, Xiaojie Yu, Mark S. Cragg, Hayden Fisher, Aymen Al-Shamkhani, Osman Dadas
Publikováno v:
Blood Cancer Discovery. 1:IA03-IA03
Agonistic antibodies directed to immunostimulatory receptors are a currently untapped source for immunotherapy. Whereas checkpoint blockers have translated into the clinic, the rules for agonistic antibodies have been more difficult to discern and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::135699569c9a53250acf43e6b28becda
https://doi.org/10.1158/2643-3249.lymphoma20-ia03
https://doi.org/10.1158/2643-3249.lymphoma20-ia03
Autor:
Anna H, Turaj, Kerry L, Cox, Christine A, Penfold, Ruth R, French, C Ian, Mockridge, Jane E, Willoughby, Alison L, Tutt, Jordana, Griffiths, Peter W M, Johnson, Martin J, Glennie, Ronald, Levy, Mark S, Cragg, Sean H, Lim
Publikováno v:
Scientific Reports
CD134 (OX40) is a member of the tumour necrosis factor receptor superfamily (TNFRSF). It acts as a costimulatory receptor on T cells, but its role on NK cells is poorly understood. CD137, another TNFRSF member has been shown to enhance the anti-tumou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1b313ace1aeaf2fcda9844cbb15d5ebe
https://pubmed.ncbi.nlm.nih.gov/29396470
https://pubmed.ncbi.nlm.nih.gov/29396470
Autor:
Anne, Rogel, Jane E, Willoughby, Sarah L, Buchan, Henry J, Leonard, Stephen M, Thirdborough, Aymen, Al-Shamkhani
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 114(7)
Immunotherapy has emerged as an important modality for the treatment of cancer, and T-cell vaccination provides an opportunity to generate a long-lasting anticancer response. Critical to this response is the generation of memory CD8+ T cells, but the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ba81f02a244f72379cd156f98005cdcb
https://pubmed.ncbi.nlm.nih.gov/28137869
https://pubmed.ncbi.nlm.nih.gov/28137869
Autor:
Stephen M. Thirdborough, Anne Rogel, Jane E. Willoughby, Sarah L. Buchan, Henry J. Leonard, Aymen Al-Shamkhani
Publikováno v:
Proceedings of the National Academy of Sciences. 114
Memory CD8+ T cells confer long-term immunity against tumors, and anticancer vaccines therefore should maximize their generation. Multiple memory CD8+ T-cell subsets with distinct functional and homing characteristics exist, but the signaling pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e803c0d35f275a4c2c3b1a534b1e9e06
https://doi.org/10.1073/pnas.1611299114
https://doi.org/10.1073/pnas.1611299114
Autor:
Sarah L. Buchan, Jane E. Willoughby, Jonathan P. Kerr, Vadim Y. Taraban, Anne Rogel, Aymen Al-Shamkhani, Peter Johnson
Publikováno v:
The Journal of Immunology. 193:244-251
The factors that determine differentiation of naive CD8 T cells into memory cells are not well understood. A greater understanding of how memory cells are generated will inform of ways to improve vaccination strategies. In this study, we analyzed the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::712b0f435da4cd47130132ceeabff487
https://doi.org/10.4049/jimmunol.1301217
https://doi.org/10.4049/jimmunol.1301217